Bardoxolone Methyl

For research use only.

Catalog No.S8078 Synonyms: RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me

17 publications

Bardoxolone Methyl Chemical Structure

CAS No. 218600-53-4

Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.

Size Price Stock Quantity  
USD 97 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bardoxolone Methyl has been cited by 17 publications

3 Customer Reviews

  • Renal Nrf2 activity was shown in RTA402-treated acFSGS (RTA402 + acFSGS) mice as early as day 7 (RTA402 + acFSGS) and persisted to day 28, compared to vehicle + acFSGS mice. Kidney in situ ROS production demonstrated by DHE detection.

    Free Radic Biol Med, 2014, 73:260-9 . Bardoxolone Methyl purchased from Selleck.

  • KG-1a cells were treated with Bar (0.5 µM) or a vehicle for 48 h and Annexin V/PI staining was detected after 48 h by flow cytometry.

    Oncol Rep, 2017, 38(3):1517-1524. Bardoxolone Methyl purchased from Selleck.

  • Cells were exposed to increasing concentrations of Bardoxolone methyl (BM; 0–1000 nM) and AR protein levels were measured. Top panels show representative immunoblots depicting AR-FL, AR-V7 and GAPDH levels. Bottom panels show fold change in AR proteins, normalized to GAPDH levels.

    Oncol Rep, 2017, 38(5):2774-2786. Bardoxolone Methyl purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.
Features The only IKKβ inhibitor in clinical use for solid tumors, type 2 diabetes, and chronic kidney disease. An orally-available antioxidant inflammation modulator.
Targets
IKK [3]
(Cell-free assay)
Ferroptosis [7]
()
Nrf2 [6]
()
NF-κB [6]
()
In vitro

Bardoxolone Methyl exhibits potent inhibitory activities against production of nitric oxide induced by interferon-Ƴ in mouse macrophages with IC50 of 0.1 nM. [1] Bardoxolone Methyl decreases the viability of leukemic HL-60, KG-1, and NB4 cells with IC50 of 0.4, 0.4, and 0.27 μM, respectively. CDDO-Me induces pro-apoptotic Bax protein, inhibits the activation of ERK1/2, and it blocks Bcl-2 phosphorylation, which contributes to the induction of apoptosis. [2] Bardoxolone Methyl potently inhibits both constitutive and inducible NF-kappaB activated by TNF, interleukin (IL)-1beta, phorbol ester, okadaic acid, hydrogen peroxide, lipopolysaccharide, and cigarette smoke. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NHfCPIlHfW6ldHnvckBie3OjeR?= MoDNTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RicILvcIln\XKjdHnvckBw\iCPQ1[tO{ApTVJiUH;zbZRqfmVrIHLy[YF{fCClYX7j[ZIh[2WubIOsJGlEPTB;MD6wOe69VQ>? M3fpRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3M{[5N|k3Lz5zNUO2PVM6PjxxYU6=
BMDM M{fETGN6fG:2b4jpZ4l1gSCjc4PhfS=> NUftN5dLOjRiaILz NFrlWZpEgXSxdH;4bYNqfHliYXfhbY5{fCCFNUfCUE83KG2xdYPlJGJOTE1iY3XscJMh[XO|ZYPz[YQh[XNiTFTIJJJmdGWjc3WgZYZ1\XJiMkSgbJJ{NCCPTmTEQVAvPc7:TR?= MlW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3M{O3PVAoRjJ{NUOzO|kxRC:jPh?=
BMDM MkTWRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? MnzlNE42KHWP MUexJIhz M{jMbmFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hSzV5QlyvOkBud3W|ZTDCUWROKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gUHBUNXO2aX31cIF1\WRiVF7GZYxxcGFicILv[JVkfGmxbjDheEAxNjVidV2gdJJmfHKnYYTl[EBnd3JiMTDodkBj\W[xcnWgUHBUKGOqYXzs[Y5o\SCjZoTldkA5KHSxIEK0JIhzeyCkeTDpcY12dm:jc4PhfS=> NVjE[48{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1N|M4QTBpPkKyOVM{PzlyPD;hQi=>
PANC1343 M{faW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M2XqeFMxOCC2bzCxNFAxKG6P NF7rdpI4OiCqcoO= MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKFCDTlOxN|Q{KGOnbHzzJIF1KDNyMDD0c{AyODByIH7NJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYm= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6OEiwOkc,OjR|OEi4NFY9N2F-
RAW264.7 MUPBcpRqd3irZHHueEBie3OjeR?= MnvyNVAxKG6P NFPiO4EyQCCqcoO= MWrBcpRqd3irZHHueEBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIITCTHAucW6mdXPl[EBTV1NicILv[JVkfGmxbjDheEAyODBibl2gdJJmfHKnYYTl[EBnd3JiMUigbJJ{KGKnZn;y[UBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgNVUhdWmwczDifUBJOkSFRlGtZoF{\WRiZnzve{BkgXSxbXX0dpk> MlvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEi4NFYoRjJ2M{i4PFA3RC:jPh?=
HepG2 MVLDfZRwfG:6aXPpeJkh[XO|YYm= NFK4TFQ1QCCqcoO= NVXYXmQ{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01Njl7zszN M1fsO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nki1OVQ2Lz5{NE[4OVU1PTxxYU6=
B16F10 Ml7OR5l1d3SxeHnjbZR6KGG|c3H5 NF;FUWo1QCCqcoO= MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlg2|ryP MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ6NUW0OUc,OjR4OEW1OFU9N2F-
CCD-841-CoN MmPBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MnPnO|IhcHK| NGXwUJVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDSE05PDFvQ3;OJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5|MUdOwG0> MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{WxOFQoRjJ3Nke1NVQ1RC:jPh?=
HCT8 NYf1NHF6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M4LiSlczKGi{cx?= M3nzU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgOU1HXSC{ZYPpd5RidnRiaIXtZY4hUEOWODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOzZ|zszN NIjDOmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OVE1PCd-MkW2O|UyPDR:L3G+
HCT8 NYTobndOSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVy3NkBpenN? MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEigZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN7Od88US=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NYThWVlOTnWwY4Tpc44h[XO|YYm= NVLkdHlLOSC3TR?= M2K1XVI1KGi{cx?= NGTNeWxKdmirYnn0bY9vKG:oIFjJSk0y[WyyaHGgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGhEXDhiY3XscJMh[XRiMTD1UUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>? M3L1TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke1NVQ1Lz5{NU[3OVE1PDxxYU6=
HCT8 NGP1TFZHfW6ldHnvckBie3OjeR?= MnWyNUB2VQ>? MYOyOEBpenN? MVXJcohq[mm2aX;uJI9nKEiLRj2xZYxxcGFicILveIVqdiCneIDy[ZN{cW:wIHnuJGZWNXKnc3nzeIFvfCCqdX3hckBJS1R6IHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDt[ZRpd2R? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 MojPSpVv[3Srb36gZZN{[Xl? NULoc|BkOSC3TR?= NXTaUphzOjRiaILz NIPGV3hKdmirYnn0bY9vKG:oIGPURXQ{KHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGhEXDhiY3XscJMh[XRiMTD1UUBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIH3leIhw\A>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 M2rIeGZ2dmO2aX;uJIF{e2G7 M1\aZlEhfU1? NH:xcHEzPCCqcoO= NGDtOFdKdmirYnn0bY9vKG:oIGPURXQ{KHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIlvKE[XLYLld4l{fGGwdDDoeY1idiCKQ2S4JINmdGy|IHH0JFEhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2dHnu[{Bu\XSqb3S= M4Lvd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke1NVQ1Lz5{NU[3OVE1PDxxYU6=
HCT8 MWfGeY5kfGmxbjDhd5NigQ>? M1LZfFEhfU1? MnzINlQhcHK| MoDuTY5pcWKrdHnvckBw\iCDS2SgdJJwfGWrbjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iSFPUPEBk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k NYHOZ5ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2O|UyPDRpPkK1Olc2OTR2PD;hQi=>
HCT8 M3PVPGZ2dmO2aX;uJIF{e2G7 NXToWll3OSC3TR?= MVGyOEBpenN? NH7GNFRKdmirYnn0bY9vKG:oIFHLWEBxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDpckBHXS2{ZYPpd5RidnRiaIXtZY4hUEOWODDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfHSrbnegcYV1cG:m M3TYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke1NVQ1Lz5{NU[3OVE1PDxxYU6=
HCT8 MWrGeY5kfGmxbjDhd5NigQ>? MnLGNUB2VQ>? MmXENlQhcHK| M2W1TmlvcGmkaYTpc44hd2ZiRWLLJJBzd3SnaX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFjDWFgh[2WubIOgZZQhOSC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NX7nO2tITnWwY4Tpc44h[XO|YYm= NFvMWIkyKHWP MmrDNlQhcHK| NW\LXZN{UW6qaXLpeIlwdiCxZjDFVmsheHKxdHXpckBxcG:|cHjvdplt[XSrb36gbY4hTlVvcnXzbZN1[W62IHj1cYFvKEiFVEigZ4VtdHNiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3S2aX7nJI1mfGixZB?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5NUG0OEc,OjV4N{WxOFQ9N2F-
HCT8 NGDUUJVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUCxJJVO M3vscVczKGi{cx?= NUTSZmFMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIF1KDFidV2gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeR?= NH6xWIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3OVE1PCd-MkW2O|UyPDR:L3G+
HCT8 M2PJWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnjjNUB2VQ>? NHjRc2Y4OiCqcoO= MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IEWtSnUhemW|aYP0ZY51KGi3bXHuJGhEXDhiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[XRiMTD1UUBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5 Mn3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{WxOFQoRjJ3Nke1NVQ1RC:jPh?=
BEAS2B NEXiSY9HfW6ldHnvckBie3OjeR?= Mk\6NVAhfU1? MVO2JIhzew>? NH3JWolC[3SrdnH0bY9vKG:oIF7y[lIhcW5iaIXtZY4hSkWDU{LCJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEiRMTDn[Y5mKGW6cILld5Nqd25iYYSgNVAhfU1iaX7jeYJifGWmIH\vdkA3KGi{czDifUByWEOUIH3leIhw\A>? NVWz[mxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yO|gxOjhpPkK2Nlc5ODJ6PD;hQi=>
H42E NV\3XoFDTnWwY4Tpc44h[XO|YYm= M4ruN|I1KGi{cx?= NEn3em1KdmS3Y4Tpc44hd2ZiTmLGNkBi[3SrdnH0bY9vKGmwIILheEBJPDKHIHPlcIx{KGW6cILld5NqdmdiQWLFPGwh[XO|ZYPz[YQh[XNicnXwc5J1\XJidILhcpNo\W6nIHHjeIl3cXS7IHHmeIVzKDJ2IHjyd{BjgSCudX3pcoV{[2WwY3WgZZN{[XluIFPEQVAvODByNd88US=> M1jZTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUC4NVc{Lz5{NkmwPFE4OzxxYU6=
H42E M3HnVWN6fG:2b4jpZ4l1gSCjc4PhfS=> M{nWUVI1KGi{cx?= NXLqSnRGS3m2b4TvfIlkcXS7IHHnZYlve3RicnH0JGg1OkViY3XscJMh\XiycnXzd4lv\yCDUlW4UEBie3Onc4Pl[EBieyClZXzseYxieiCDVGCgcIV3\WxiYX\0[ZIhOjRiaILzJIJ6KEOnbHz0bZRmei2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52zszN M1r4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUC4NVc{Lz5{NkmwPFE4OzxxYU6=
H42E Ml3BSpVv[3Srb36gZZN{[Xl? NVHrUZdwOC5yMTD0c{A{OCCwTR?= MVWxJIhz MXLTeIFjcWyrenH0bY9vKG:oIF7SSlIhcW5icnH0JGg1OkViY3XscJMh\XiycnXzd4lv\yCDUlW4UEBifCByLkCxJJRwKDNyIH7NJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz NIrrOHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkmwPFE4Oyd-Mk[5NFgyPzN:L3G+
NHBE NUHJ[5ZwS3m2b4Dyc5Rm[3SrdnWgZZN{[Xl? NFPIWWcxNjByMTD0c{AxNjFidV2= NIDrS4MyQCCqcoO= MWHDfZRweHKxdHXjeIl3\SCjY4Tpeol1gSCrbjDOTGJGKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geGJJWC2rbnT1Z4VlKEeVSDDk[ZBt\XSrb36gZZQhOC5yMEGgeI8hOC5zIIXNJJBz\WmwY4XiZZRm\CCob4KgNVghcHK|IH\vcIxwf2WmIHL5JJRDUFBiYXTkbZRqd25iZn;yJFQhcHK|IHL5JJRpcW:|dHHyJIR6\SCkYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZk> NV;oZ4poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewN|E3PzBpPkK3NFMyPjdyPD;hQi=>
NHBE NGTtOo1HfW6ldHnvckBie3OjeR?= NXe2OHFMOTByIH7N MYiyOEBpenN? MnO2TY5pcWKrdHnvckBw\iCNRVHQNU9PWkZ{IHnueIVz[WO2aX;uJIlvKE6KQlWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hT0OOTTDtVm5CKGW6cILld5Nqd25iYYSgNVAxKG6PIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIlvKHC{ZYPlcoNmKG:oIH7vckB1[XKpZYTpcoche2mUTlGgZpkheVKWLWDDVkBu\XSqb3S= MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyM{G2O|AoRjJ5MEOxOlcxRC:jPh?=
NHBE NHf0eWlHfW6ldHnvckBie3OjeR?= NVfWfYoyOTByIH7N MYqyOEBpenN? NIHtd|ZKdmirYnn0bY9vKG:oIFvFRXAyN06URkKgbY51\XKjY4Tpc44hcW5iTljCSUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCQUV:xJI1TVkFiZYjwdoV{e2mxbjDheEAyODBibl2gbY5kfWKjdHXkJIZweiB{NDDodpMhcW5icILld4Vv[2Vib3[gco9vKHSjcnfleIlv\yC|aWLORUBjgSCzUmStVGNTKG2ndHjv[C=> NVvpdWpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewN|E3PzBpPkK3NFMyPjdyPD;hQi=>
NHBE MVzGeY5kfGmxbjDhd5NigQ>? NH3yO48yODBibl2= MYK0PEBpenN? M3XQV2lvcGmkaYTpc44hd2ZiS1XBVFEwVlKIMjDpcpRmemGldHnvckBqdiCQSFLFJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCQUV:xJJNx\WOrZnnjJIFkfGm4aYT5JIF1KDFyMDDuUUBqdmO3YnH0[YQh\m:{IES4JIhzeyCrbjDwdoV{\W6lZTDv[kBvd25idHHy[4V1cW6pIIPpVm5CKGK7IF3UWEBz\WS3Y4Tpc44h[XO|YYm= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB|MU[3NEc,OjdyM{G2O|A9N2F-
HaCaT-ARE-luc NUHGU5k5TnWwY4Tpc44h[XO|YYm= NHP0eHA3KGi{cx?= NGT0VllC[3SrdnH0bY9vKG:oIF7y[lIhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hUGGFYWStRXJGNWy3YzDj[YxteyCjZoTldkA3KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5yNt88US=> NEfjR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEe1N|I6PCd-Mki3OVMzQTR:L3G+
NIH/3T3 M3;ZRmZ2dmO2aX;uJIF{e2G7 M1jEXFYhcHK| NIX5PYNKdmirYnn0bY9vKG:oIGTOSk1idHCqYTDzeIlufWyjdHXkJG5HNWujcIDhRkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDZiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTygTWM2OD1zLkNOwG0> NWPjfZQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVMzQTRpPkK4O|U{Ojl2PD;hQi=>
HeLa MnWxSpVv[3Srb36gZZN{[Xl? NXjUOVI5PiCqcoO= NIXUeYFKdmirYnn0bY9vKG:oIFnGUk1o[W2vYTDzeIlufWyjdHXkJHNVSVR|IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiNjDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUKuN|jPxE1? MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NUOyPVQoRjJ6N{WzNlk1RC:jPh?=
RAW264.7 M4HM[WFvfGlvaX7mcIFudWG2b4L5JIF{e2G7 M4PmdGFvfGlvaX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44tKEmFNUC9OO69VQ>? NV:3Xm86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVQ1PzBpPkK4O|U1PDdyPD;hQi=>
HEK293 MlnyR5l1d3SxeHnjbZR6KGG|c3H5 NHzVUnMzPCCqcoO= M3[4WmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlLPxE1? MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl7NEK4Okc,Ojh7OUSyPFY9N2F-
H9c2 NHfhPVlEgXSxdH;4bYNqfHliYYPzZZk> Mmq4NlQhcHK| NHTjbHZEgXSxdH;4bYNqfHliYXfhbY5{fCC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02NjMQvF2= M{fUNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUm0Nlg3Lz5{OEm5OFI5PjxxYU6=
HEK293 MmXLSpVv[3Srb36gZZN{[Xl? NX7ES3NjOjByIITvJFExODBibl2= NE\GXJMzPCCqcoO= NH;CcY9KdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgWG5H[WyyaHGtbY5lfWOnZDDOSotieHCjQjDhZ5RqfmG2aX;uJIF1KDJyMDD0c{AyODByIH7NJIFldWmwaYP0[ZJm\CB4IHjyd{Bi\nSncjDUUmZidHCqYTDzeIlufWyjdHnvckBu\WG|dYLl[EBnd3JiMkSgbJJ{KGK7IF7Gb4FxeGGELXTybZZmdiCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYm= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl7NEK4Okc,Ojh7OUSyPFY9N2F-
HEK293 NHXMfmRHfW6ldHnvckBie3OjeR?= M3TrNFIxOCC2bzCxNFAxKG6P MXuyOEBpenN? NFXqcnFKdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFSQRnHsdIhiNWmwZIXj[YQhfXC{ZXf1cIF1cW:wIH;mJIlPV1NibWLORUBmgHC{ZYPzbY9vKGG2IEKwNEB1dyBzMECwJI5OKGGmbXnubZN1\XKnZDC2JIhzeyCjZoTldkBVVk[jbIDoZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCob4KgNlQhcHK|IHL5JJF2[W62aYTheIl3\SCUVD3QR3Ih[W5? NEX0UFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 Moj6SpVv[3Srb36gZZN{[Xl? NF7hNHgzODBidH:gNVAxOCCwTR?= MXOyOEBpenN? NEPUdJlKdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFSQRnHsdIhiNWmwZIXj[YQhfXC{ZXf1cIF1cW:wIH;mJGNQYDJibWLORUBmgHC{ZYPzbY9vKGG2IEKwNEB1dyBzMECwJI5OKGGmbXnubZN1\XKnZDC2JIhzeyCjZoTldkBVVk[jbIDoZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCob4KgNlQhcHK|IHL5JJF2[W62aYTheIl3\SCUVD3QR3Ih[W5? NEPhWlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 M2DhbGZ2dmO2aX;uJIF{e2G7 MlzINlAxKHSxIEGwNFAhdk1? NXHlenV6OjRiaILz NIDmWFNKdmirYnn0bY9vKG:oIFnLT4JmfGFiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFSQRnHsdIhiNWmwZIXj[YQhfXC{ZXf1cIF1cW:wIH;mJG1EWDFibWLORUBmgHC{ZYPzbY9vKGG2IEKwNEB1dyBzMECwJI5OKGGmbXnubZN1\XKnZDC2JIhzeyCjZoTldkBVVk[jbIDoZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCob4KgNlQhcHK|IHL5JJF2[W62aYTheIl3\SCUVD3QR3Ih[W5? NXrFU2szRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
intraglomerular mesangial cells MULGeY5kfGmxbjDhd5NigQ>? NUHzNll7OC54NTDt[{9s\w>? NHG1XJEyOiC5ZXXrdy=> M4j3b3Jmdm:ycn;0[YN1cX[nIHHjeIl3cXS7IHnuJIRjN2SkIH3veZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJI52dWKncjDv[kBqdnS{YXfsc41menWuYYKgcYV{[W6paXHsJINmdGy|IHH0JFAvPjVibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EB1emmlZTDw[ZIhf2WnazDmc5IhOTJiY3;ud4VkfXSrdnWge4Vmc3NibXXhd5Vz\WRiYYSgNVEhf2Wna4OgdI9{fCCmb4PlJIJ6KEhxRT3zeIFqdmmwZzDiZZNm\CCvaXPyc5Nkd3CrYzDhcoFtgXOrcx?= NXfBb3JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 NFrWUXBHfW6ldHnvckBie3OjeR?= NF\adJIzODBidH:gNVAxOCCwTR?= M2TUblI1KGi{cx?= Moi3TY5pcWKrdHnvckBw\iCLS1vi[ZRiKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBVVk[jbIDoZU1qdmS3Y3XkJJVxemWpdXzheIlwdiCxZjDDU3gzKHC{b4TlbY4h\XiycnXzd4lwdiCjdDCyNFAhfG9iMUCwNEBvVSCjZH3pcol{fGW{ZXSgOkBpenNiYX\0[ZIhXE6IYXzwbIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiZn;yJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l NIfVPY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 NF7mfnJHfW6ldHnvckBie3OjeR?= Ml21NlAxKHSxIEGwNFAhdk1? MYOyOEBpenN? MXzJcohq[mm2aX;uJI9nKEmNS3LleIEhMHWwa37ve44hd3KrZ3nuLUB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHRPTmGucHjhMYlv\HWlZXSgeZBz\We3bHH0bY9vKG:oIHnOU3MheHKxdHXpckBmgHC{ZYPzbY9vKGG2IEKwNEB1dyBzMECwJI5OKGGmbXnubZN1\XKnZDC2JIhzeyCjZoTldkBVVk[jbIDoZUB{fGmvdXzheIlwdiCvZXHzeZJm\CCob4KgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> NWLXbnFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 Ml3oSpVv[3Srb36gZZN{[Xl? MWeyNFAhfG9iMUCwNEBvVQ>? NGTEWo8zPCCqcoO= MmC4TY5pcWKrdHnvckBw\iCLS1vi[ZRiKCi3bnvuc5dvKG:{aXfpckkhfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IH3peIlo[XSrb36gc4YhXE6IYXzwbIEucW6mdXPl[EBqdmO{ZXHz[UBqdiC{YYTpc{Bw\iCwdXPs[YFzKHSxIHP5eI9{d2yrYzDwOlUh[XRiMkCwJJRwKDFyMECgcm0h[WSvaX7pd5RmemWmIE[gbJJ{KGGodHXyJHRPTmGucHjhJJN1cW23bHH0bY9vKG2nYYP1doVlKG[xcjCyOEBpenNiYomgW4V{fGW{bjDicI91 NF3iOWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 M2fKSmZ2dmO2aX;uJIF{e2G7 M13DV|IxOCC2bzCxNFAxKG6P MoTrNlQhcHK| NXfXW2VHUW6qaXLpeIlwdiCxZjDJT2tj\XSjIDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hUEWNMkmzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCWTl\hcJBp[S2rbnT1Z4VlKHWycnXneYxifGmxbjDv[kBOS1BzIIDyc5RmcW5iZYjwdoV{e2mxbjDheEAzODBidH:gNVAxOCCwTTDh[I1qdmm|dHXy[YQhPiCqcoOgZYZ1\XJiVF7GZYxxcGFic4TpcZVt[XSrb36gcYVie3W{ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m Mnu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7OUSyPFYoRjJ6OUm0Nlg3RC:jPh?=
HEK293 MXfGeY5kfGmxbjDhd5NigQ>? MXOyNFAhfG9iMUCwNEBvVQ>? MnfWOFghcHK| NV:3ZpQ1UW6qaXLpeIlwdiCxZjDL[YFxOS:Qcn[yJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IIXwdoVofWyjdHnvckBw\iCKTz2xJI1TVkFiZYjwdoV{e2mxbjDheEAzODBidH:gNVAxOCCwTTDh[pRmeiB2ODDodpMh[nlicYXhcpRqfGG2aY\lJHJVNVCFUjDhcoFtgXOrcx?= NGHNWow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 NUTDW29sTnWwY4Tpc44h[XO|YYm= NF32RpYzODBidH:gNVAxOCCwTR?= Moj0OFghcHK| NWPSTo1yUW6qaXLpeIlwdiCxZjDL[YFxOS:Qcn[yJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IIXwdoVofWyjdHnvckBw\iCQUV:xJI1TVkFiZYjwdoV{e2mxbjDheEAzODBidH:gNVAxOCCwTTDh[pRmeiB2ODDodpMh[nlicYXhcpRqfGG2aY\lJHJVNVCFUjDhcoFtgXOrcx?= NIPCVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm5OFI5Pid-Mki5PVQzQDZ:L3G+
HEK293 MmHrSpVv[3Srb36gZZN{[Xl? MVqyNFAhfG9iMUCwNEBvVQ>? MnjqOFghcHK| NVS3SHNtUW6qaXLpeIlwdiCxZjDL[YFxOS:Qcn[yJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHHjeIl3[XSrb36gc4YhVnKoMjDheEAzODBidH:gNVAxOCCwTTDh[pRmeiB2ODDodpMh[nliQWLFMYRzcX[nbjDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl7NEK4Okc,Ojh7OUSyPFY9N2F-
HEK293 M{DmbWZ2dmO2aX;uJIF{e2G7 M1f0T|IxOCC2bzCxNFAxKG6P MYi0PEBpenN? NEjDSnJKdmirYnn0bY9vKG:oIFvlZZAyN06{ZkKgLJVvc26xd36gc5Jq\2mwKTDpcpRmemGldHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcpVkdGWjcjD0c{BkgXSxc3;sbYMhVm[{MjDyZZRqdyCjdDCyNFAhfG9iMUCwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NVPrc4JHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 MmjhSpVv[3Srb36gZZN{[Xl? MlLyNlAxKHSxIEGwNFAhdk1? M2nSeFQ5KGi{cx?= MnW3TY5pcWKrdHnvckBw\iCNZXHwNU9PemZ{IDj1cotvd3ewIH;ybYdqdiliaX70[ZJi[3Srb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHP5eI9{d2yrYzDIU{0yKGyndnXsd{BifCB{MECgeI8hOTByMDDuUUBi\nSncjC0PEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NVT1S5NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
HEK293 M4XDbmZ2dmO2aX;uJIF{e2G7 NG\afXozODBidH:gNVAxOCCwTR?= MV[0PEBpenN? NWT4e2o2UW6qaXLpeIlwdiCxZjDL[YFxOS:Qcn[yJEh2dmuwb4fuJI9zcWerbjmgbY51\XKjY4Tpc44hfHKjboPm[YN1\WRiaX6gTGVMOjl|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIN6fG:|b3zpZ{BPWU9zIHzleoVteyCjdDCyNFAhfG9iMUCwNEBvVSCjZoTldkA1QCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NX;Vco1vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5PVQzQDZpPkK4PVk1Ojh4PD;hQi=>
A549/TR NXrscVJlSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1vWPFczKGi{cx?= MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmvWHIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zLkewN:69VQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMUm0O{c,Ojl3MEG5OFc9N2F-
A549 MkPaRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlPEO|IhcHK| MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0zNjB5NN88US=> MorjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MEG5OFcoRjJ7NUCxPVQ4RC:jPh?=
A549/TR Mn3KSpVv[3Srb36gZZN{[Xl? MUmyMlQhfG9iOT62JJVO Mn;ZNlQhcHK| MV3JcoR2[3Srb36gc4YhWk:VIHflcoVz[XSrb36gbY4hcHWvYX6gRVU1QS:WUjDj[YxteyCjdDCyMlQhfG9iOT62JJVOKGGodHXyJFI1KGi{czDifUBFS0[KLVTBJIR6\S2kYYPl[EBndG:5IHP5eI9u\XS{aXOgZY5idHm|aYO= NV31d2h1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFE6PDdpPkK5OVAyQTR5PD;hQi=>
A549/TR MkLwSpVv[3Srb36gZZN{[Xl? M{nQRlQvQCC3TR?= NFHTbZczPCCqcoO= NHTFR|FFd3ewcnXneYxifGmxbjDv[kBNd25iZYjwdoV{e2mxbjDpckBpfW2jbjDBOVQ6N1SUIHPlcIx{KGG2IESuPEB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MEG5OFcoRjJ7NUCxPVQ4RC:jPh?=
HCT116 MlL5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3XCPVczKGi{cx?= MnK0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OD1yLkCwNFI2|ryP MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1N{c,OzB2Mkm5OVM9N2F-
HT-29 MVzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MYe3NkBpenN? Mn\0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMklOwG0> NYTJfokzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTNpPkOwOFI6QTV|PD;hQi=>
HCT8 M1q2WGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NHHD[pY4OiCqcoO= M1\DXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUPEBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMkpOwG0> NV;Qe5V{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C0Nlk6PTNpPkOwOFI6QTV|PD;hQi=>
HCT116 NYixeJV4TnWwY4Tpc44h[XO|YYm= M4XxeVghcHK| NH;jSI1KdmirYnn0bY9vKG:oIFLtbVEheHKxdHXpckBmgHC{ZYPzbY9vKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NIXFc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Oyd-M{C0Nlk6PTN:L3G+
BEAS2B Mli0SpVv[3Srb36gZZN{[Xl? M3LnV|Q5KGi{cx?= MoLwRYN1cX[jdHnvckBw\iCNZXHwNU9EfWx|L17y[lIhcW5iaIXtZY4hSkWDU{LCJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKE6TT{GgcIV3\Wy|IH3lZZN2emWmIHHmeIVzKDR6IHjyd{whTUN3ME2wMlAxQDdzzszN MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODZ{NkW1OUc,OzB4Mk[1OVU9N2F-
HepG2 NGHBTIpEgXSxdH;4bYNqfHliYYPzZZk> MV60PEBpenN? NVe0U21FS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkK2{txO MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB3MUSwNUc,OzFyNUG0NFE9N2F-
MCF7 NHfZXoJEgXSxdH;4bYNqfHliYYPzZZk> M2rG[FQ5KGi{cx?= NEXhU5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5|Nd88US=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{OTB3MUSwNUc,OzFyNUG0NFE9N2F-
A549 NX65RXhUS3m2b4TvfIlkcXS7IHHzd4F6 M1;WTlQ5KGi{cx?= NVjYVHRiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTBwM{dOwG0> M1rmb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNzMEWxOFAyLz5|MUC1NVQxOTxxYU6=
A549 M{\lPWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NXm2dZlSPDhiaILz NVHVemlmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuOVLPxE1? NG\TfFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUeyOVI5QCd-M{G3NlUzQDh:L3G+
HepG2 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3T4OFQ5KGi{cx?= M2O5Z2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD61Nu69VQ>? MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF5MkWyPFgoRjNzN{K1Nlg5RC:jPh?=
HOS NI\wbFFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NW[ySIdLPDhiaILz MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiRUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjZ4zszN NXi2dXJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{G3NlUzQDhpPkOxO|I2Ojh6PD;hQi=>
MCF7 NY\ab5VwSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NEnKT2w1QCCqcoO= NXzoWWhUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCpcn;3eIghcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuPFXPxE1? NITwVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUeyOVI5QCd-M{G3NlUzQDh:L3G+
HEK293FT Ml;RSpVv[3Srb36gZZN{[Xl? M2fuZVI1KGi{cx?= M2jqcmlvcGmkaYTpc44hd2ZibX;1d4UhT0:DVDDlfJBz\XO|ZXSgbY4hUEWNMkmzSnQh[2WubIOgZ48u\XiycnXzd4lv\yCycnWtdJJw\2i{ZXzpckBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4hz\WyrbjDvZ5Ridm:7bHH0bY9vKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JGVNUVODLDDJR|UxRTBwMEO1{txO M4XaWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE4PjJ4MkGvK|5EcEWPQly8M4E,

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-IκBα / IκBα ; 

PubMed: 25897966     


HeLa cells were pre-treated with RTA 408 or bardoxolone methyl for 6 hours at the indicated concentrations followed by a five-minute treatment with TNFα. Protein levels of phospho-IκBα and total IκBα were evaluated by western blot. Actin was used as loading control. Data are representative of four experiments.

Bcl-xl / Bcl-2 / Bax / Cleaved caspase / Cytochrome C / PARP / Cleaved PARP ; 

PubMed: 25733817     


Representative blots of respective proteins measured to show the effect of CDDO-Me treatment on the expression levels of Bcl-xl, Bcl-2, Bax, PUMA, cytochrome c, cleaved caspase-3 (active), cleaved caspase-9 (active), PARP, and cleaved PARP in Ec109 and KYSE70 cells determined using Western blotting analysis. 

p-PI3K / PI3K / p-AMPK / AMPK / p-p38 MAPK / p38 MAPK / p-AKT / AKT / p-mTOR / mTOR; 

PubMed: 25733817     


Effects of CDDO-Me treatment on the expression levels of p-PI3K at Tyr458, PI3K, p-AMPK at Thr172, AMPK, p-p38 at Thr180, p38, p-Akt at Ser473, Akt, p-mTOR at Ser2448, mTOR, PTEN, beclin 1, LC3-I, and LC3-II in Ec109 and KYSE70 cells. Cellular lysates were analyzed by immunoblotting with respective first antibody followed by the second antibody. 

PTEN / PP2A / PHLPP1 ; 

PubMed: 22177954     


LNCaP and PC-3 cells were treated with CDDO-Me (0.3-5 µM) for 20 h and cell lysates were analyzed for PTEN, PP2A and PHLPP1 by immunoblotting. 

25897966 25733817 22177954
Immunofluorescence
PDI / SDHA ; 

PubMed: 26053096     


MDA-MB 435 cells were treated with or without 1.5 μM CDDO-Me for indicated time points. Immunocytochemistry using anti-PDI (red) and anti-SDHA (green) antibodies was performed and the representative fluorescence and phase contrast microscopic images of cells are shown. Scale bar: 20 μm.

c-PARP / Cytochrome C / COX IV; 

PubMed: 26053096     


E, F. MDA-MB 435 cells were untreated or treated with 1.5 μM CDDO-Me for 24 h. Immunocytochemistry of the cleaved PARP and staining with DAPI were performed (E). Immunocytochemistry of the cytochrome c (Cyt.c) and the subunit I of cytochrome c oxidase (COX IV) was performed (F) Representative fluorescence microscopic images of cells are shown. Scale bars: 50 μm.

26053096
Growth inhibition assay
Cell viability ; 

PubMed: 25733817     


(A) The chemical structure of CDDO-Me and (B) effects of CDDO-Me on the proliferation of Ec109, KYSE70, and Het-1A cells determined by the MTT assay. Notes: Cells were treated with CDDO-Me at 0.01, 0.05, 0.25, 1.0, and 5.0 μM for 24 or 48 hours. Data are the mean ± SD of at least four independent experiments.

25733817
In vivo

Bardoxolone Methyl (60 mg/kg) reduces the number, size, and severity of lung tumors in vivo. [4] Bardoxolone Methyl significantly reduces the in vivo inflammatory cytokine response following LPS challenge, induces HO-1 protein expression in the spleen, and protects mice against lethal-dose LPS. [5]

Protocol

Kinase Assay:

[3]

- Collapse

IKK assay :

To determine the effect of CDDO-Me on TNF-induced IKK activation, IKK is analyzed. Briefly, the IKK complex from whole-cell extracts was precipitated with antibody against IKKα and IKKβ and then treated with protein A/G-Sepharose beads. After 2 hours, the beads are washed with lysis buffer and then resuspended in a kinase assay mixture containing 50 mmol/L HEPES (pH 7.4), 20 mmol/L MgCl2, 2 mmol/L DTT, 20 μCi [γ-32P]ATP, 10 μmol/L unlabeled ATP, and 2 μg of substrate glutathione S-transferase-IκBα (amino acids 1-54). After incubation at 30°C for 30 minutes, the reaction is terminated by boiling with SDS sample buffer for 5 minutes. Finally, the protein is resolved on 10% SDS-PAGE, the gel is dried, and the radioactive bands are visualized with a Storm820. To determine the total amounts of IKK-α and IKK-β in each sample, 50 μg of whole-cell proteins are resolved on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then blotted with either anti-IKK-α or anti-IKK-β antibody.
Cell Research:

[2]

- Collapse
  • Cell lines: HL-60, KG-1, and NB4 cells
  • Concentrations: ~5 μM
  • Incubation Time: 72 hours
  • Method:

    Leukemic cell lines are cultured at a density of 3.0 × 105 cells/mL, and AML mononuclear cells are cultured at 5 × 105 cells/mL in the presence or absence of indicated concentrations of CDDO-Me. Appropriate amounts of DMSO (final concentration less than 0.05%) are included as control. For cytotoxicity studies, 1 μM ara-C is added to the cultures. After 24 to 72 hours, viable cells are counted with the trypan blue dye exclusion method using a hematocytometer.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female A/J mice are injected i.p. with vinyl carbamate.
  • Dosages: ~60 mg/kg
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 21 mg/mL (41.52 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4%DMSO+30% PEG300+5% Tween+61%ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 505.69
Formula

C32H43NO4

CAS No. 218600-53-4
Storage powder
in solvent
Synonyms RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me
Smiles CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)C(=O)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02316821 Completed Drug: RTA 402|Drug: Placebo Chronic Kidney Disease|Type 2 Diabetes Kyowa Kirin Co. Ltd. December 2014 Phase 2
NCT01053936 Completed Drug: Bardoxolone methyl (amorphous dispersion) Renal Insufficiency Chronic|Diabetes Mellitus Type 2 Reata Pharmaceuticals Inc. January 2010 Phase 2
NCT00811889 Completed Other: Placebo|Drug: Bardoxolone Methyl (RTA 402) Chronic Kidney Disease|Type 2 Diabetes|Diabetic Nephropathy Reata Pharmaceuticals Inc. April 2009 Phase 2
NCT00664027 Completed Drug: RTA 402 (Bardoxolone Methyl) Diabetic Nephropathy Reata Pharmaceuticals Inc. April 2008 Phase 2
NCT00550849 Terminated Drug: RTA 402 Liver Disease Reata Pharmaceuticals Inc. April 2007 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

Related IκB/IKK Products

Tags: buy Bardoxolone Methyl | Bardoxolone Methyl supplier | purchase Bardoxolone Methyl | Bardoxolone Methyl cost | Bardoxolone Methyl manufacturer | order Bardoxolone Methyl | Bardoxolone Methyl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID